Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/6/2011

CAMBRIDGE, Mass., Sept. 6, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), announced today that Idenix management will present a corporate overview at the Morgan Stanley Global Healthcare Conference on September 13 at 8:35 a.m. ET at the Grand Hyatt, New York City and at the Bank of America Merrill Lynch Global Healthcare Conference on September 16, 2011 at 8:55 a.m. GMT at the Bank of America Merrill Lynch Financial Centre, London.  

The live and archived webcasts of the company presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conferences.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
2. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
3. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
4. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
5. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
6. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
7. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
9. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
10. Idenix Pharmaceuticals Reports First Quarter Financial Results
11. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):